Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Nuveen Select Tax-Free Income Portfolio is a closed-ended fixed income mutual fund launched by Nuveen Investments Inc. The fund is co-managed by Nuveen Fund Advisors LLC and Nuveen Asset Management, LLC. It invests in the fixed income markets of United States. The fund invests in the investment-grade municipal securities rated Baa and BBB or better. It benchmarks the performance of its portfolio against the Standard & Poor's (S&P) National Municipal Bond Index and Lipper General and Insured Unleveraged Municipal Debt Funds Average. Nuveen Select Tax-Free Income Portfolio was formed on March 19, 1992 and is domiciled in the United States.

Nuveen Select Tax-Free Income Portfolio

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

EINDHOVEN, THE NETHERLANDS, JULY 28, 2026 (GLOBE NEWSWIRE) -- NXP SEMICONDUCTORS N.V. (NASDAQ: NXPI) TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER, WHICH ENDED JUNE 28, 2026. NXP DELIVERED SECOND-QUARTER REVENUE OF $3.5 BILLION, UP 19 PERCENT YEAR-ON-YEAR AND 10 PERCENT SEQUENTIALLY, WITH GROWTH ACROSS ALL END MARKETS AND ALL REGIONS. THIS PERFORMANCE REFLECTS THE STRENGTH OF OUR COMPANY-SPECIFIC GROWTH DRIVERS, PARTICULARLY IN SOFTWARE-DEFINED VEHICLES AND PHYSICAL AI, WITH DATA CENTER EMERGING AS AN ADDITIONAL GROWTH ENGINE. OUR STRONG FIRST-HALF RESULTS AND THIRD-QUARTER GUIDANCE REINFORCE OUR CONFIDENCE IN ACHIEVING OUR FINANCIAL COMMITMENTS TO DRIVE LONG-TERM SHAREHOLDER VALUE. UNDERLYING THESE RESULTS, AI IS MOVING FROM THE CLOUD INTO THE PHYSICAL WORLD  INTO VEHICLES, FACTORIES, AND ROBOTS  AND IT LANDS DIRECTLY IN THE MARKETS WHERE NXP HAS LEADERSHIP POSITIONS. NXP'S PORTFOLIO OF PROCESSING, CONNECTIVITY, AND SECURITY SOLUTIONS, POSITIONS US TO ENABLE NEXT-GENERATION EDGE INTELLIGENCE FOR OUR CUSTOMERS, SAID RAFAEL SOTOMAYOR, NXP PRESIDENT AND CHIEF EXECUTIVE OFFICER.

NXP SEMICONDUCTORS REPORTS SECOND QUARTER 2026 RESULTS

FIRST GLOBAL APPROVAL OF A ONCE-DAILY, ORALLY ADMINISTERED, COMPLEMENT FACTOR B INHIBITOR APPROVAL BASED ON ROBUST EFFICACY AND SAFETY DATA FROM HAISCO'S BROAD COMPLETED CLINICAL DEVELOPMENT PROGRAM IN PNH CIPROCOPAN APPLICATION FOR MARKETING APPROVAL IN CHINA FOR THE TREATMENT OF PATIENTS WITH PNH PREVIOUSLY TREATED WITH ANTI-C5 THERAPIES IS CURRENTLY UNDER REVIEW CIPROCOPAN HAS THE POTENTIAL TO BECOME AN EFFECTIVE THERAPY IN MULTIPLE COMPLEMENT-MEDIATED DISEASES AND PROVIDE A CONVENIENCE ADVANTAGE AS A ONCE-DAILY ORAL TREATMENT OPTION FOR PATIENTS REQUIRING CONTINUOUS LIFE-LONG TREATMENT FORT LEE, NJ, JULY 23, 2026 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT) (NUVECTIS OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE THERAPIES FOR THE TREATMENT OF COMPLEMENT-RELATED CONDITIONS AND ONCOLOGY, TODAY ANNOUNCED THAT CIPROCOPAN (NXP100), A ONCE-DAILY ORAL COMPLEMENT FACTOR B INHIBITOR, RECEIVED MARKETING APPROVAL FROM THE NATIONAL MEDICINAL PRODUCTS ADMINISTRATION OF CHINA (NMPA) FOR THE TREATMENT OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PREVIOUSLY UNTREATED WITH COMPLEMENT INHIBITORS (TREATMENT NAIVE). AS THE WORLD'S FIRST APPROVED ONCE-DAILY ORAL COMPLEMENT FACTOR B INHIBITOR, CIPROCOPAN OFFERS PATIENTS LIVING WITH PNH A NEW, EFFECTIVE, SAFE AND CONVENIENT TREATMENT OPTION AND PROVIDES IMPORTANT CLINICAL AND REGULATORY VALIDATION AND FURTHER SUPPORTS THE THERAPEUTIC POTENTIAL OF ONCE-DAILY ORAL FACTOR B INHIBITION IN PNH AND OTHER COMPLEMENT MEDIATED DISEASES.

CORRECTION: (TITLE CORRECTION) NUVECTIS ANNOUNCES MARKETING APPROVAL OF CIPROCOPAN (NXP100) IN CHINA FOR THE TREATMENT OF PATIENTS WITH PNH PREVIOUSLY UNTREATED WITH COMPLEMENT INHIBITORS

FORT LEE, NJ, JULY 23, 2026 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT) (NUVECTIS OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE THERAPIES FOR THE TREATMENT OF COMPLEMENT-RELATED CONDITIONS AND ONCOLOGY, TODAY ANNOUNCED THAT CIPROCOPAN (NXP100), A ONCE-DAILY ORAL COMPLEMENT FACTOR B INHIBITOR, RECEIVED MARKETING APPROVAL FROM THE NATIONAL MEDICINAL PRODUCTS ADMINISTRATION OF CHINA (NMPA) FOR THE TREATMENT OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PREVIOUSLY UNTREATED WITH COMPLEMENT INHIBITORS (TREATMENT NAIVE).

CIPROCOPAN (NXP100) RECEIVES MARKETING APPROVAL IN CHINA FOR THE TREATMENT OF PATIENTS WITH PNH PREVIOUSLY UNTREATED WITH COMPLEMENT INHIBITORS

NEW REPORT COVERS NUVECTIS PHARMA (NASDAQ: NVCT) AS THE COMPANY TRANSITIONS FROM A SINGLE-DRUG ONCOLOGY STORY INTO A LATE-STAGE RARE-DISEASE PLAYER FOLLOWING ITS JUNE LICENSING DEAL WITH HAISCO PHARMACEUTICAL GROUP. REPORT HIGHLIGHTS: NUVECTIS PHARMA (NASDAQ: NVCT) RECENTLY SECURED WORLDWIDE RIGHTS OUTSIDE CHINA TO NXP100, A POTENTIALLY BEST-IN-CLASS ONCE-DAILY ORAL THERAPY FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH), ALONG WITH ONCOLOGY ASSET NXP200, FROM HAISCO PHARMACEUTICAL GROUP.

STREETWATCH: NUVECTIS PHARMA EYES $9.8 BILLION ORAL PNH MARKET WITH LATE-STAGE NXP100 BACKED BY STRONG POSITIVE PHASE 3 DATA

EINDHOVEN, THE NETHERLANDS, JULY 07, 2026 (GLOBE NEWSWIRE) -- NXP SEMICONDUCTORS N.V. (NASDAQ: NXPI) TODAY ANNOUNCED IT WILL RELEASE FINANCIAL RESULTS FOR THE SECOND QUARTER 2026 AFTER THE CLOSE OF NORMAL TRADING ON THE NASDAQ GLOBAL SELECT MARKET ON TUESDAY, JULY 28, 2026.

NXP SEMICONDUCTORS ANNOUNCES CONFERENCE CALL TO REVIEW SECOND QUARTER 2026 FINANCIAL RESULTS

EINDHOVEN, THE NETHERLANDS, JUNE 24, 2026 (GLOBE NEWSWIRE) -- NXP SEMICONDUCTORS N.V. (NASDAQ: NXPI) TODAY ANNOUNCED THAT JEFF PALMER, SENIOR VICE PRESIDENT OF INVESTOR RELATIONS, HAS DECIDED TO RETIRE FOLLOWING A DISTINGUISHED 16-YEAR CAREER WITH THE COMPANY. FOLLOWING JEFF'S RETIREMENT, MIKE LUCARELLI WILL SERVE AS SENIOR VICE PRESIDENT OF INVESTOR RELATIONS. MIKE WILL REPORT TO BILL BETZ, CHIEF FINANCIAL OFFICER, SERVING AS A KEY LIAISON TO THE INVESTMENT COMMUNITY.

NXP SEMICONDUCTORS' JEFF PALMER TO RETIRE, MIKE LUCARELLI NAMED SENIOR VICE PRESIDENT OF INVESTOR RELATIONS

BELGRADE, SERBIA--(BUSINESS WIRE)--QUECTEL WIRELESS SOLUTIONS, A GLOBAL END-TO-END IOT SOLUTIONS PROVIDER, TODAY ANNOUNCES THE LAUNCH OF THE FCM365X, A DUAL BAND WI-FI 6 AND BLUETOOTH LOW ENERGY (BLE) 5.4 MODULE THAT IS BASED ON THE NXP SEMICONDUCTORS RW612 WIRELESS MCU AND SUPPORTS MULTIPLE PROTOCOLS, INCLUDING ZIGBEE AND THREAD. THE MODULE IS POWERED BY A HIGH-PERFORMANCE ARM CORTEX-M33 PROCESSOR WITH TRUSTZONE TECHNOLOGY, OPERATING AT UP TO 260MHZ. IT INTEGRATES 1.2MB OF SRAM AND 8MB OF.

QUECTEL INTRODUCES NXP-BASED FCM365X WI-FI 6, BLUETOOTH LE 5.4, ZIGBEE AND THREAD MODULE FOR SMART HOME AND INDUSTRIAL IOT SOLUTIONS

EINDHOVEN, THE NETHERLANDS, JUNE 11, 2026 (GLOBE NEWSWIRE) -- AS PART OF ITS ONGOING CAPITAL RETURN PROGRAM, NXP SEMICONDUCTORS N.V. (NASDAQ: NXPI) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS APPROVED THE PAYMENT OF AN INTERIM DIVIDEND.

NXP SEMICONDUCTORS ANNOUNCES QUARTERLY DIVIDEND

EINDHOVEN, THE NETHERLANDS, APRIL 28, 2026 (GLOBE NEWSWIRE) -- NXP SEMICONDUCTORS N.V. (NASDAQ: NXPI) TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER, WHICH ENDED MARCH 29, 2026. NXP DELIVERED QUARTERLY REVENUE OF $3.18 BILLION, UP 12% YEAR OVER YEAR, WITH BROAD-BASED IMPROVEMENT ACROSS ALL OF OUR FOCUS END MARKETS, LED BY OUR COMPANY-SPECIFIC GROWTH DRIVERS. OUR GROWTH REFLECTS SUSTAINED INVESTMENT, DISCIPLINED EXECUTION, AND GROWING CUSTOMER ADOPTION OF OUR DIFFERENTIATED PORTFOLIO, PARTICULARLY IN INDUSTRIAL AND AUTOMOTIVE PROCESSING THAT SUPPORTS SOFTWARE-DEFINED VEHICLES AND PHYSICAL AI. THE MOMENTUM WE HAVE BUILT IS EXPECTED TO ACCELERATE THROUGH THE REMAINDER OF 2026, WITH PROGRESS INCREASINGLY EXTENDING ACROSS THE CORE OF OUR BUSINESS. WE REMAIN COMMITTED TO DISCIPLINED INVESTMENT, MARGIN EXPANSION, AND PORTFOLIO OPTIMIZATION TO DELIVER SUSTAINABLE, LONG-TERM VALUE FOR OUR SHAREHOLDERS, SAID RAFAEL SOTOMAYOR, NXP PRESIDENT AND CHIEF EXECUTIVE OFFICER.

NXP SEMICONDUCTORS REPORTS FIRST QUARTER 2026 RESULTS

EINDHOVEN, THE NETHERLANDS, APRIL 27, 2026 (GLOBE NEWSWIRE) -- NXP SEMICONDUCTORS N.V. (NASDAQ: NXPI) WILL HOLD ITS ANNUAL MEETING OF SHAREHOLDERS ON WEDNESDAY, JUNE 10, 2026 AT 8:30 A.M. CET AT THE COMPANY'S HEADQUARTERS, HIGH TECH CAMPUS 60, 5656 AG, EINDHOVEN, THE NETHERLANDS.

Nuveen Select Tax-Free Income Portfolio

NXP

Price

Financial Reports

No items found.

Press Releases

Nuveen Select Tax-Free Income Portfolio

NXP.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

NXP